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OBJECTIVES We tested a hypothesis that elevation of the plasma level of brain natriuretic peptide (BNP)
is one of the characteristics of patients with diastolic heart failure (DHF) independent of left
ventricular (LV) hypertrophy.
BACKGROUND The clinical characteristics of DHF are not well acknowledged, although DHF has become
a great social burden. Such a lack of clinical information leads to inaccuracy in the diagnosis
of DHF. We have demonstrated enhancement of ventricular production of BNP with
progression of maladaptive ventricular hypertrophy, but not with development of compen-
satory hypertrophy in an animal DHF model.
METHODS Of 372 patients who presented to the emergency department because of acute pulmonary
congestion without acute coronary syndrome between January 1996 and May 2002, those
with an ejection fraction45% upon admission, who were stably controlled at least for a year
in our outpatient clinics, comprised the DHF group (n  19). A control group consisted of
22 hypertensive patients with a LV mass index greater than or equal to its minimum value of
the DHF group and an ejection fraction45%, in whom cardiac symptoms had not occurred.
RESULTS Despite a similar distribution of LV mass index, the BNP level was higher in the DHF group
than in the control group (149  38 vs. 31  5 pg/ml, p  0.01). There was no difference
in LV cavity size or parameters derived from pulsed Doppler transmitral flow velocity curves.
CONCLUSIONS An elevation of BNP may be a hallmark of patients with or at risk of DHF among subjects
with preserved systolic function independent of LV hypertrophy. (J Am Coll Cardiol 2004;
43:55–60) © 2004 by the American College of Cardiology Foundation
The clinical syndrome of congestive heart failure (HF)
occurs over a broad range of underlying left ventricular (LV)
systolic function (1–4). Heart failure with normal or min-
imally impaired systolic function is attributed to diastolic
dysfunction and is termed “diastolic heart failure” (DHF). It
frequently occurs in the community, particularly in the
elderly population, and leads to a poor prognosis (1,2,5–7).
Thus, the economic impact of DHF is substantial (8,9), and
there is a growing interest in this type of HF. Noninvasive
methods, including Doppler echocardiography, cannot pro-
vide unequivocal evidence of LV diastolic dysfunction
(10,11), and DHF has not yet been well characterized.
These account for an absence of practical and definitive
diagnostic criteria for DHF. Currently, the diagnosis of
DHF is made primarily on the basis of symptoms and
exclusion criteria (12). However, symptoms such as exer-
tional dyspnea, paroxysmal nocturnal dyspnea, and pedal
edema are not specific to HF. Some may well argue against
the diagnostic criteria (13). The doubt about the diagnosis
has limited the recognition of the clinical and social impor-
tance of DHF.
Hypertensive heart disease is a major underlying cardio-
vascular disease in DHF (1,2), and LV hypertrophy is likely
related to DHF (14). However, a population-based cohort
survey demonstrated that 20% of patients with LV hy-
pertrophy progress to HF (4). Experimental and clinical
studies suggest that LV hypertrophy can be divided into at
least two types—adaptive and maladaptive hypertrophy—
the latter being closely related to HF (15–17). Currently,
maladaptive hypertrophy cannot be detected in clinical
settings.
Brain natriuretic peptide (BNP) is a cardiac neurohor-
mone specifically secreted from the ventricles (18). Eleva-
tion of the plasma BNP level is considered to reflect
ventricular structural and functional alterations. Although
its clinical utility as a biochemical marker of LV systolic
dysfunction has been reported (19–21), its positive predic-
tive value was only 10% to 20%. Previous in vitro studies
showed a close relationship between BNP production and
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myocyte hypertrophy (22,23). Of interest is that adaptive
hypertrophy did not promote ventricular BNP production
in Dahl salt-sensitive rats, and the promotion was provided
only in the presence of maladaptive LV hypertrophy with
fibrosis that led to symptomatic overt DHF (24). We tested
a hypothesis that elevation of plasma BNP is one of the
characteristics of patients with or at risk of DHF among
subjects with preserved LV systolic function.
METHODS
Selection of patients. To enroll patients with a history of
definitive overt DHF (DHF group) from the institutional
medical records, we identified patients who presented to our
hospital’s emergency department with definitive pulmonary
edema with preserved systolic function between January
1996 and May 2002. During this period, 372 patients had
an acute onset of dyspnea, respiratory distress, and pulmo-
nary rales due to pulmonary congestion, as confirmed by
chest radiography, in the absence of an acute coronary
syndrome. Of these patients, those who met the following
entry criteria were identified: 1) echocardiographic confir-
mation of ejection fraction (EF) 45% on admission; and
2) release of symptoms by treatment with diuretics and/or
vasodilators after the emergent admission. Patients with
congenital heart disease, severe valve disease, or renal failure
(serum creatinine concentration 2.0 mg/dl) or those who
were not followed up in our outpatient clinics were ex-
cluded. The plasma BNP level temporarily increases with
worsening of HF and gradually decreases after relief of
symptoms. To exclude the effects of such fluctuational
changes in plasma BNP level in association with acute
worsening of HF, patients who were hospitalized within a
year before the study enrollment were also excluded. Among
the patients who met these criteria, the DHF group in this
study comprised 16 patients who were hospitalized between
January 1996 and January 2001 and agreed to participate in
this study in January 2002, as well as three patients who
were hospitalized between February 2001 and May 2002
and agreed to participate in May 2003. All of these patients
were stable when they participated in this study. Two
patients in the DHF group (11%) had a history of coronary
artery disease. They had undergone a successful percutane-
ous coronary intervention before the episode of acute
pulmonary congestion. At and after the emergent admis-
sion, there was no significant change in their electrocardio-
gram and no increase in plasma levels of troponin T and the
MB isoenzyme of creatine kinase. They underwent coronary
angiography after the release of the symptoms, and no
significant coronary stenosis was found.
As a control group, 22 consecutive hypertensive patients
referred for echocardiography who met all of the following
criteria were included: 1) no symptoms of HF up to the
study enrollment; 2) EF 45%; 3) a ratio of LV mass to
body surface area (LV mass index) greater than or equal to
the minimum value of LV mass index in the DHF group;
and 4) 50 years old, because all the patients of the DHF
group were 50 years old. These criteria were used because
EF, LV mass index, and age are likely to individually affect
the plasma BNP level (19–21,25), and their differences
between groups will make it difficult to assess a relationship
between plasma BNP level and DHF. Patients with severe
valve disease or renal failure (serum creatinine concentration
2.0 mg/dl) were excluded. This study was approved by the
institutional ethics committee, and all participants gave
written, informed consent.
Study protocol. In the both groups, conventional transtho-
racic echocardiography and blood assay were conducted.
Medications were not withheld before this study for ethical
reasons.
Transthoracic echocardiographic examinations were con-
ducted to measure left atrial and LV cavity sizes and LV
wall thickness, as previously described (20,26,27). Ejection
fraction was calculated by a modification of the method of
Quinones et al. (28), and LV mass was calculated according
to the formula derived from the data of the American
Society of Echocardiography (29), as previously described
(20,27). In patients with sinus rhythm, the pulsed Doppler
transmitral flow velocity curve was recorded to measure a
ratio of peak mitral E-wave velocity to peak mitral A-wave
velocity (E/A ratio) and the deceleration time of the mitral
E-wave velocity (27).
Phlebotomy was performed to measure plasma concen-
tration of neurohormones. Plasma concentrations of atrial
natriuretic peptide (ANP) and BNP were measured using
immunoradiometric assay with commercially available kits
(Shionogi Co. Ltd., Osaka, Japan). Plasma renin activity
and aldosterone level were measured using radioimmunoas-
say with commercially available kits (Dainabot Co. Ltd.,
Tokyo, Japan). The plasma norepinephrine concentration
was measured by high-performance liquid chromatography.
Statistical analysis. Values are expressed as mean  SEM.
All statistical analyses were performed using a commercially
available statistical software (STATVIEW version 5.0, SAS
Institute Inc., Cary, North Carolina). Discrete variables
were summarized by frequency percentages and analyzed
with the chi-square test. Differences between the two
groups were assessed using the Student t test. Results were
considered statistically significant at p  0.05.
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
DHF  diastolic heart failure
E/A  ratio of peak mitral E-wave velocity to peak
mitral A-wave velocity
EF  ejection fraction
HF  heart failure
LV  left ventricular
NYHA  New York Heart Association
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RESULTS
Patient characteristics of the DHF and control groups at the
time of the study enrollment are summarized in Table 1.
There were no significant differences in age or gender
between the two groups. All of the patients in the both
groups had a history of hypertension, and there was no
difference in systolic and diastolic blood pressures in the
outpatient clinics.
The LV end-diastolic and end-systolic dimensions, EF,
and wall thicknesses of the interventricular septum and LV
posterior wall were not different between the groups. The
LV mass index was similarly distributed between the groups
(Fig. 1). The E/A ratio and deceleration time of the mitral
E-wave velocity were not different. The left atrial dimension
was significantly larger in the DHF group than in the
control group.
Plasma BNP and ANP levels were significantly higher in
the DHF group than in the control group (Fig. 1). There
was no difference in the plasma levels of norepinephrine,
renin activity, or aldosterone (Fig. 2).
At the time of study enrollment, 12 patients in the DHF
group were in New York Heart Association (NYHA)
functional class I; 5 patients were in class II; and 2 patients
were in class III. The BNP level was significantly higher in
the 12 patients of the DHF group with NYHA class I than
in the control group (96  29 vs. 31  5 pg/ml, p  0.01).
In contrast, the statistical significance disappeared when the
ANP level (52  14 vs. 31  3 pg/ml, p  0.08) or left
atrial dimension (40  2 vs. 38  1 mm, p  0.23) was
compared between the 12 DHF patients with NYHA class
I and the control group.
DISCUSSION
Diastolic HF occurs in a high proportion of patients with
HF and causes significant mortality and morbidity (1,2,5,6).
It accounts for more than 25% of the total HF cost (8,9),
and its prevalence may further increase as the population
becomes older. The mortality impact of DHF was greater
than that of HF with reduced EF (i.e., systolic HF) among
community-dwelling elderly persons (7). However, diag-
nostic criteria for DHF have not been defined. The current
consensus is that the assessment of LV diastolic function
with the analysis of transmitral flow velocity curves has
many limitations (10–12), particularly in patients with
preserved EF (27,30). In fact, the diagnostic criteria for
Table 1. Patient Characteristics of Both Groups
Control
Group
(n  22)
DHF
Group
(n  19)
Age (yrs) 66  2 72  3
Women (%) 59 68
Medications (%)
ACE inhibitors 45 53
Angiotensin II receptor antagonists 36 37
Calcium channel blockers 68 63
Diuretics 18 79*
Beta-blockers 23 37
Other vasodilators 18 32
Clinical history (%)
Hypertension 100 100
Coronary artery disease 0 11
Diabetes mellitus 5 11
Atrial fibrillation (%) 0 16
Systolic blood pressure (mm Hg) 133  4 132  4
Diastolic blood pressure (mm Hg) 77  2 72  2
Left ventricular end-diastolic
dimension (mm)
50  1 49  2
Left ventricular end-systolic
dimension (mm)
32  1 31  1
Left ventricular ejection fraction (%) 68  2 63  2
Interventricular septal thickness (mm) 12  1 12  1
Left ventricular posterior wall
thickness (mm)
11  1 11  1
E/A ratio 0.79  0.06 0.80  0.06
Deceleration time of mitral
E-wave velocity (ms)
196  7 218  16
Left atrial dimension (mm) 38  1 44  2*
Serum creatinine level (mg/dl) 0.8  0.1 1.0  0.1
*p  0.05 versus control group. Data are presented as the mean  SEM.
ACE  angiotensin-converting enzyme; DHF  diastolic heart failure; E/A 
ratio of peak mitral E-wave velocity to peak mitral A-wave velocity.
Figure 1. Comparison of the left ventricular (LV) mass index, plasma brain
natriuretic peptide (BNP) level, and plasma atrial natriuretic peptide
(ANP) level between the two groups. The vertical bars indicate the range
of values. The middle horizontal bars indicate means, and the upper and
lower horizontal bars indicate standard errors (SEM).
Figure 2. Comparison of plasma norepinephrine level, plasma renin
activity, and plasma aldosterone level between the two groups. The vertical
bars indicate the range of values. The middle horizontal bars indicate
means, and the upper and lower horizontal bars indicate standard errors
(SEM). DHF  diastolic heart failure.
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diastolic dysfunction, as proposed in several previous stud-
ies, are not consistent (14,31–33). The diagnosis based on
symptoms of HF despite preserved EF is widely used but is
argued against because the symptoms are not specific to HF
(13). Thus, objective information on clinical characteristics
of DHF is required to provide a reliable diagnosis.
To minimize the effects of such inconsistency in the
diagnosis in the current study, the DHF group in this study
consisted of patients who met the following criteria: 1) a
history of acute onset of dyspnea, respiratory distress, and
pulmonary rales due to pulmonary congestion, as confirmed
by chest radiography; and 2) echocardiographic confirma-
tion of preserved EF on admission. The current results show
that the LV chamber dimension, LV mass index, and
parameters derived from the transmitral flow velocity curves
in the DHF group were not different from those in the
control group consisting of hypertensive patients who had
been asymptomatic. In contrast, the plasma BNP level was
significantly higher in the DHF group than in the control
group. Elevation of the plasma BNP level in symptomatic
DHF patients was reported (3,34), but the DHF patients in
these studies had LV hypertrophy. Previous in vitro and in
vivo studies showed a close relationship between BNP
production and myocyte hypertrophy (20,22,23); thus, it
was unclear in their study whether the increased BNP level
was due to LV hypertrophy or characteristic of DHF
independent of LV hypertrophy. As LV hypertrophy is
frequently associated with DHF (1,2,14), it is a clinically
important issue whether BNP is increased in DHF patients
beyond the level that is produced by LV hypertrophy alone.
The current study expanded the previous findings by dem-
onstrating that elevation of plasma BNP is not attributed to
LV hypertrophy alone. This result is partly compatible with
a previous study by Lang et al. (35), who demonstrated an
increase in plasma BNP level in symptomatic DHF patients
with ischemic heart disease in the absence of LV hypertro-
phy. This study also showed that the plasma BNP level
stayed elevated in the DHF group, even after symptoms of
HF were controlled to NYHA class I. Thus, the elevation of
plasma BNP is likely a hallmark of patients with or at risk
of DHF among subjects with preserved EF.
Left ventricular hypertrophy may be classified into adap-
tive and maladaptive hypertrophy, and the pharmacologic
suppression of maladaptive hypertrophy prevented the tran-
sition to overt DHF, despite the presence of adaptive
hypertrophy (16,36). Our experimental studies suggest that
adaptive hypertrophy was induced at least partly through
activation of calcineurin (37), and that maladaptive hyper-
trophy was provided by activation of the renin-angiotensin
and endothelin systems (16,36). Another experimental
study showed development of adaptive LV hypertrophy in
the presence of pressure overload in angiotensin II type
1-receptor knockout mice (38). Previous in vitro studies
showed that BNP production is enhanced in myocytes by
adding G-protein–coupled neurohormones such as angio-
tensin II, endothelin-1, and phenylephrine (22,39), and
ventricular BNP production was promoted by maladaptive,
not adaptive, LV hypertrophy in hypertensive rats (24).
Maladaptive hypertrophy was associated with progressive
LV fibrosis that leads to myocardial stiffening (40). Tamura
et al. (41) showed that pressure overload induced more
progressive ventricular fibrosis in mice genetically lacking in
BNP, as compared with wild mice. These findings suggest
a close relationship between BNP production and ventric-
ular fibrosis. Clarkson et al. (34) reported beneficial effects
of short-term administration of BNP in patients with
symptomatic DHF patients. Thus, elevation of plasma BNP
in the DHF group may indicate the presence of maladaptive
hypertrophy and/or progressive ventricular fibrosis, both of
which play crucial roles in the development of DHF, and
the enhanced production of BNP may act as a protective
mechanism in DHF patients.
In this study, the plasma ANP level was also higher in the
DHF patients than in the asymptomatic hypertensive pa-
tients with a similar LV mass index. Left atrial dimension
was significantly enlarged in the DHF group. Because
plasma ANP is mainly secreted from the atria (18), left atrial
overload due to LV diastolic dysfunction may have enlarged
the left atrium to elevate the plasma ANP level. Thus, an
elevated plasma ANP level and enlarged left atrial dimen-
sion are likely another characteristic of DHF among sub-
jects with preserved EF. However, in contrast to BNP,
increases in these parameters are not beyond the level
expected by the effects of LV hypertrophy alone in asymp-
tomatic patients. The norepinephrine level was not different
between the DHF and control groups. Kitzman et al. (3)
showed that the norepinephrine level was higher in DHF
patients than in normal healthy controls. All of the DHF
patients in their study were symptomatic. In contrast, more
than half of the patients in the DHF group were controlled
to NYHA class I in this study, although all of the patients
had a history of acute pulmonary congestion. Even in
symptomatic patients, most were controlled to NYHA class
II. Ross et al. (42) demonstrated a decrease in plasma
norepinephrine to a normal level in association with the
improvement of congestive HF by medical therapy in
patients with congenital heart disease. These may at least
partly explain an absence of the difference in norepinephrine
level between the DHF and control groups in this study.
Study limitations. There are some limitations of this
study. First, the number of study subjects is not large. The
DHF group in this study included only patients who had a
definitive history of acute pulmonary edema under echocar-
diographic confirmation of EF 45% on admission and
were still followed up by our outpatient clinics. The plasma
BNP level temporarily increases with worsening HF and
gradually decreases after relief of symptoms. The effects of
such fluctuations in BNP were avoided by selecting patients
who experienced acute pulmonary congestion more than
one year before the study enrollment. Such strict inclusion
criteria are responsible for the small number of the subjects
but have minimized the effects of inaccuracy in the diagnosis
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of DHF that have been frequently debated in the discussion
of the reliability of the conclusions of DHF studies.
Second, it is unclear whether the current findings can be
extrapolated to patients with mild symptoms due to diastolic
dysfunction and without a history of acute pulmonary
edema. However, the current results suggest that a future
prospective study with a large number of subjects to analyze
the utility of plasma BNP as a diagnostic or predictive tool
for DHF is promising.
Third, there was no significant difference in the param-
eters derived from Doppler echocardiography, except for left
atrial dimension, between the DHF and control groups in
this study. Redfield et al. (43) recently demonstrated that
diastolic dysfunction defined by combined analysis of pulsed
Doppler transmitral and pulmonary venous flow velocity
curves and tissue Doppler imaging of mitral annular motion
represented a poor prognosis. Because pulmonary venous
flow velocity curves and mitral annular motion were not
analyzed in this study, the current study does not necessarily
deny the value of the additional Doppler echocardiographic
parameters in characterizing patients with DHF. The prin-
cipal purpose of this study was to test a hypothesis that
elevation of plasma BNP is characteristic of patients with or
at risk of DHF among subjects with preserved LV systolic
function, and the lack of the analysis of such additional
Doppler echocardiographic parameters should not lessen
the clinical implication of this study.
Conclusions. We found that the plasma BNP level was
elevated in patients with a history of acute pulmonary edema
due to DHF independent of LV hypertrophy. Their BNP
levels were still high even after their symptoms were
controlled to NYHA class I. Thus, the elevation of BNP
may be a hallmark of patients with or at risk of DHF among
subjects with preserved LV systolic function.
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